• All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests
• Four of five completed patients (80%) were negative on highly sensitive post-treatment NAT testing
• Results reinforce favorable retreatment-free outcomes reported with tafenoquine–atovaquone regimens
• Two additional patients remain on treatment, bringing total enrollment to seven; study remains open pending potential discussions with FDA

WASHINGTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced clinical and molecular results from the first five patients to complete treatment with tafenoquine-containing combination regimens in the Company’s expanded access study of relapsing babesiosis in immunosuppressed patients.

All five patients reported being much improved or very much improved on study-completion forms, and each had negative conventional polymerase chain reaction (PCR) test results for Babesia documented during treatment or subsequent follow-up. Four of the five patients (80%) were also nonreactive on a highly sensitive blood-donor nucleic acid amplification test (NAT) for Babesia performed on blood collected after treatment. The remaining patient had a reactive blood-donor NAT despite a negative follow-up conventional PCR result from Mayo Clinic.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.